Mannose-binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 89-96

  Frakking, F N J ^a,b   Israels J ^a   Kremer, L C M ^a   Kuijpers, T W ^b   Caron, H N ^a   van de Wetering, M D ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cancer: febrile neutropenia; Infection; Innate immunity; Lectin; Mannose binding

Indexed keywords

MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; DISEASE DURATION; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LEUKEMIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; MALE; MANNOSE-BINDING LECTIN; MEDLINE; MYCOSES; NEOPLASMS; NEUTROPENIA; RISK FACTORS; VIRUS DISEASES;

EID: 79955730685     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22901     Document Type: Article

References (32)

1. Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999;106:436-444.
2. Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002;38:S82-S87.
3. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005;40:S240-S245.
4. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997;99:580-588.
5. Ben AR, Toren A, Ono N, et al. Predictors of outcome in the pediatric intensive care units of children with malignancies. J Pediatr Hematol Oncol 2002;24:23-26.
6. Hartel C, Deuster M, Lehrnbecher T, et al. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer 2007;49:767-773.
7. Jones GR, Konsler GK, Dunaway RP, et al. Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol 1996;13:217-229.
8. Brouwer N, Frakking FN, van de Wetering MD, et al. Mannose-binding lectin (MBL) substitution: Recovery of opsonic function in vivo lags behind MBL serum levels. J Immunol 2009;183:3496-3504.
9. Frakking FNJ, van de Wetering MD, Brouwer N, et al. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 2006;42:909-916.
10. Neth O, Jack DL, Dodds AW, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000;68:688-693.
11. Saifuddin M, Hart ML, Gewurz H, et al. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000;81:949-955.
12. Takahashi K, Ip WE, Michelow IC, et al. The mannose-binding lectin: A prototypic pattern recognition molecule. Curr Opin Immunol 2006;18:16-23.
13. Brouwer N, Dolman KM, van Zwieten R, et al. Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop. Mol Immunol 2006;43:2051-2060.
14. Summerfield JA, Sumiya M, Levin M, et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-1232.
15. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003;37:1496-1505.
16. Kielgast S, Thiel S, Henriksen TB, et al. Umbilical cord mannan-binding lectin and infections in early childhood. Scand J Immunol 2003;57:167-172.
17. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003;40:423-429.
18. Israëls J, Frakking FNJ, Kremer LC, et al. Mannose-binding lectin and infection risk in neonates, a systematic review. Arch Dis Child Fetal Neonatal Ed 2010;95:F452-F461.
19. Chaudhry SH, Chaudhry S, Jansen-Hoogendijk AM, et al. Mannose-binding lectin levels and infections in children after allogeneic hematopoietic SCT. Bone Marrow Transplant 2010;45:289-293.
20. Neth O, Jack DL, Johnson M, et al. Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannose-binding lectin-associated serine protease after binding to Staphylococcus aureus. J Immunol 2002;169:4430-4436.
21. Frakking FN, Brouwer N, van Eijkelenburg NK, et al. Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis. Clin Exp Immunol 2007;150:255-262.
22. Schlapbach LJ, Aebi C, Otth M, et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer 2007;49:11-16.
23. Garred P, Larsen F, Madsen HO, et al. Mannose-binding lectin deficiency-Revisited. Mol Immunol 2003;40:73-84.
24. Grimes DA, Schulz KF. Cohort studies: Marching towards outcomes. Lancet 2002;359:341-345.
25. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-437.
26. Laupacis A, Wells G, Richardson WS, et al. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 1994;272:234-237.
27. Lausen B, Schmiegelow K, Andreassen B, et al. Infections during induction therapy of childhood acute lymphoblastic leukemia-No association to mannose-binding lectin deficiency. Eur J Haematol 2006;76:481-487.
28. Lehrnbecher T, Venzon D, De HM, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999;29:414-419.
29. Neth O, Hann I, Turner MW, et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001;358:614-618.
30. Rubnitz JE, Howard SC, Willis J, et al. Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatr Blood Cancer 2008;50:866-868.
31. Bergmann OJ, Christiansen M, Laursen I, et al. Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 2003;70:91-97.
32. Turner MW, Super M, Singh S, et al. Molecular basis of a common opsonic defect. Clin Exp Allergy 1991;21:182-188.